IgGenix is a biotechnology company.
IgGenix has raised $40.0M in total funding. The most recent round was Series B. The last funding was announced in February 2023.
IgGenix's investors include Eli Lilly, Khosla Ventures, Global Brain Corporation, Shangbay Capital, Alexandria Venture Investments.
IgGenix is headquartered in San Francisco, United States.
IgGenix is a biotechnology company.
IgGenix is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IgGenix — Funding & Investors." VCBacked, February 6, 2023, https://www.vcbacked.co/company/iggenix. Accessed July 30, 2026.
VCBacked. (2023). IgGenix — Funding & Investors. Retrieved July 30, 2026, from https://www.vcbacked.co/company/iggenix
{{cite web |title=IgGenix — Funding & Investors |url=https://www.vcbacked.co/company/iggenix |website=VCBacked |access-date=July 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated